Related Experiment Video

Updated: May 19, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond

Benjamin J Epstein1, Paul T Leonard, Niren K Shah

  • 1Department of Pharmacotherapy and Translational Research, University of Florida, PO Box 100487, Gainesville, FL 32610, USA. epstein@cop.ufl.edu

Expert Review of Cardiovascular Therapy
|August 17, 2012
PubMed

Insights

Chronic activation of the renin-angiotensin-aldosterone system (RAAS) significantly impacts cardiometabolic risk and kidney function. RAAS inhibition therapies are crucial for managing cardiovascular disease and renal dysfunction.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Endocrinology

Background:

  • Chronic activation of the renin-angiotensin-aldosterone system (RAAS) contributes to cardiovascular disease, renal dysfunction, and cardiometabolic risk.
  • Sustained RAAS activation leads to vascular issues like fibrosis, endothelial dysfunction, and cellular remodeling.

Purpose of the Study:

  • To provide a historical overview of the evolution of RAAS inhibitors.
  • To discuss the established role and expanding treatment landscape of RAAS inhibition.
  • To explore recently discovered functions of RAAS components.

Main Methods:

  • Review of historical data and clinical practice of RAAS inhibition therapies.
  • Analysis of the mechanisms of action for ACE inhibitors, ARBs, and direct renin inhibitors.
  • Discussion of current understanding and future directions in RAAS modulation.

Main Results:

  • RAAS inhibition therapies have been clinically used for over 30 years.
  • These therapies are essential for reducing the risk of cardiovascular and renal diseases.
  • Understanding of RAAS inhibition has expanded treatment options.

Conclusions:

  • RAAS inhibition is a cornerstone in managing cardiovascular and renal diseases.
  • Continued research into RAAS components reveals new therapeutic targets.
  • RAAS inhibitors play a vital role in mitigating cardiometabolic risk and preventing organ damage.

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...